|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-10-25
|
|
pubmed:abstractText |
Interferon-alpha (IFN-alpha) has shown significant activity in the treatment of BCR-ABL-negative myeloproliferative disorders (MPDs), particularly essential thrombocythemia (ET) and polycythemia vera (PV). PEG-IFN-alpha-2b is a pegylated IFN-alpha-2b with a significant advantage over nonpegylated form in that it is administered once a week.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BeranMiloslavM,
pubmed-author:CortesJorgeJ,
pubmed-author:FaderlStefanS,
pubmed-author:FerrajoliAlessandraA,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:GilesFrancisF,
pubmed-author:JabbourEliasE,
pubmed-author:KantarjianHagopH,
pubmed-author:RichieMary AnnMA,
pubmed-author:ThomasDeborahD,
pubmed-author:VerstovsekSrdanS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2012-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17849460-Antineoplastic Agents,
pubmed-meshheading:17849460-Female,
pubmed-meshheading:17849460-Fusion Proteins, bcr-abl,
pubmed-meshheading:17849460-Humans,
pubmed-meshheading:17849460-Hypereosinophilic Syndrome,
pubmed-meshheading:17849460-Interferon-alpha,
pubmed-meshheading:17849460-Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative,
pubmed-meshheading:17849460-Male,
pubmed-meshheading:17849460-Middle Aged,
pubmed-meshheading:17849460-Myeloproliferative Disorders,
pubmed-meshheading:17849460-Polyethylene Glycols,
pubmed-meshheading:17849460-Recombinant Proteins,
pubmed-meshheading:17849460-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
|
|
pubmed:affiliation |
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
